Several groups have conducted vaccine studies solely targeting FAP, demonstrating that S. typhimuirum-, plasmid-, or DC-based FAP vaccines have antitumor activity in preventive or early therapeutic settings, modulate the tumor microenvironment by promoting Th1 polarization and enhancing the infiltration of CD8-positive T cells [13], [14], [18], [25]. This evidence concerns the gene CD8A and neoplasm.